PDGFRA and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib and other PDGFRα inhibitors have been used in a wide variety of model systems and clinical studies (e.g., SCI, stroke, MS, retinal neovascularization, fibrosis, CML, GI stromal tumors, glioblastoma) to address effects on the immune response (Buchdunger et al., 2002; Ma et al., 2011; Hayashi et al., 2012; Adzemovic et al., 2013; Kjell et al., 2015; Roskoski, 2018; Cohen et al., 2021).